Medlab Clinical (ASX:MDC) EPS (Diluted) : A$-1.71 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical EPS (Diluted)?

Medlab Clinical's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was A$-0.87. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.71.

Medlab Clinical's EPS (Basic) for the six months ended in Dec. 2023 was A$-0.87. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.71.

Medlab Clinical's EPS without NRI for the six months ended in Dec. 2023 was A$-0.87. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.71.

During the past 3 years, the average EPS without NRIGrowth Rate was 30.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -42.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Medlab Clinical's highest 3-Year average EPS without NRI Growth Rate was 30.70% per year. The lowest was -355.20% per year. And the median was -22.10% per year.

Medlab Clinical EPS (Diluted) Historical Data

The historical data trend for Medlab Clinical's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical EPS (Diluted) Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EPS (Diluted)

Get a 7-Day Free Trial

-5.81

-8.91

-6.27

-471.00

-2.97

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial												-1.34	-1.80	-2.13	-0.84	-0.87

Competitive Comparison of Medlab Clinical's EPS (Diluted)

For the Biotechnology subindustry, Medlab Clinical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's PE Ratio falls into.

Medlab Clinical EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Medlab Clinical's Diluted EPS for the fiscal year that ended in Jun. 2023 is calculated as

Diluted EPS (A: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-6.778	-	0)	/	2.284
	=	-2.97

Medlab Clinical's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1.981	-	0)	/	2.284
	=	-0.87

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-1.71

Medlab Clinical (ASX:MDC) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Medlab Clinical EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (ASX:MDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.